InVivo Therapeutics (NSDQ:NVIV) said today that a patient enrolled in January in its Inspire study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the 7th patient from the 11-patient group to have an AIS grade improvement with at least 1-month of follow-up.
2 other patients have not yet had their 1-month follow-up visit, according to the Cambridge, Mass.-based company. InVivo added that the AIS conversation rate observed in its Inspire study is “considerably higher” than the rates found in a range of spinal cord injury natural history databases.
The company reported that in addition to the conversion, the patient has experienced improvements in sensory and motor function. Prior to surgery, InVivo said the patient had no sensory function on the front of the legs from below the knee and no sensory function on the back of the body from below the waist.
At the 2-month follow-up point, the patient could move their hips and knees bilaterally and had regained at least some sensory function in their lower legs, feet and back of the body from below the waist.
“It has been rewarding to be a part of the Inspire study and to follow this patient’s recovery,” principal investigator Dr. Travis Dumont said in prepared remarks. “This patient had a very low thoracic neurological level of injury, and such patients have the best prognosis. Nonetheless, I have been impressed with this patient’s recovery to date and am hopeful that the positive trajectory will continue.”
“We are excited to announce the 7th AIS conversion in the INSPIRE study,” chairman & CEO Mark Perrin added. “We are equally pleased that this patient has experienced considerable motor and sensory improvement over the first 2 months following injury. We look forward to following the patient’s progress and hope for continued recovery.”
NVIV shares were trading at $4.17 in mid-afternoon trading today, up 2.9%.